First loss realized

The very dissapointing release this morning from TDC forces me to sell it with a loss. More to follow I'm selling the entire position at 29.75 DKK

Read more.

---
Mens vi leder efter grunde til at sælge Genmab....

Mens vi leder efter grunde til at sælge Genmab....

  Medicinalgiganten Johnson & Johnson kom med sit 4. kvartal regnskab for 2015, som vi behandler i lyset af deres partnerskab med danske Genmab. Stemningen på markedet er ikke det bedste sted for biotekinvesteringer, så vi kigger sammen med mange andre på grunde til at casen i Genmab ikke udvikler sig i det blue sky scenario som markedet forventer. For …

Read more.

---

Protector Forsikring er en stjerneaktie

Protector Forsikring har i dag offentliggjort deres forventninger til 2016: "Protector Forsikring ASA, 22% growth in 2016 The January 1st renewal date is significant for Protector Forsikring, therefore we issue a volume statement to the market. The Company experiences its best year ever January 1st renewal and expects Gross Written Premiums to increase 22% over full year 2016, including a …

Read more.

The gateway to small- and midcap stocks in Scandinavia. Steen has more than 15 years hands-on expericence in analysing and investing in stocks. He is a weekly contributor and analyst in “Aktieugebrevet”, one of the leading sources of independent analysis in Denmark.

Peter Hildebrandt, also known as “Akademikeren”, has been investing for more than 17 years. Mainly invests in Undervalued technology and biotech stocks and is currently rotating towards dividend stocks in energy and shipping.

I’m a ten year veteran of biotechnology, and currently pursuing my MBA from UCLA.  I use my knowledge of the industry and business to make my investing decisions.  I look for small to mid-cap biotech companies with innovative research and buy into their company during clinical trials.

Andreas is providing stock tips with deep fundamental research behind each stock he recommends. He is privately a portfolio manager at his own Investment company where he Invest in stocks, options, CFD’s etc. with a balanced long/short approach.

Jacob’s approach is to search for that which is undervalued and where the discount to the intrinsic value provides a large margin of safety. He believes sectors that are either out of favor or in distress typically offer the best opportunities.